---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-22-000036"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2022-10-27T23:59:59+00:00"
generated_at: "2026-06-23T00:35:10.739441+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vertex Q3 product revenue $2.33B (+18% YoY); raises FY22 guidance to $8.8-8.9B

## Summary
- Product revenue $2.334B, up 18% from Q3 2021; TRIKAFTA/KAFTRIO contributed $2.011B.
- GAAP diluted EPS $3.59; non-GAAP diluted EPS $4.01, up 14% YoY.
- Full-year 2022 product revenue guidance raised to $8.8-8.9B from prior $8.6-8.7B.
- Initiating global regulatory submissions for exa-cel (sickle cell/beta thalassemia) in 2022; Phase 3 for VX-548 (acute pain) started.
- Cash and marketable securities $11.5B as of Sept 30, 2022.

## SEC filing metadata
- accession: 0000875320-22-000036
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2022-10-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532022000036/0000875320-22-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532022000036/vrtx-20221027.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-22-000036
- JSON: https://secwatch.observer/filing/0000875320-22-000036.json
- Plain text: https://secwatch.observer/filing/0000875320-22-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.